ReviewFrontiers in pharmacology2016
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Prediction of the survival status and tumor microenvironment in colorectal cancer through genotyping analysis based on toll-like receptors.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024Article
- Review
- WGS Data Collections: How Do Genomic Databases Transform Medicine?International journal of molecular sciences · 2023Review
- The construction and analysis of tricarboxylic acid cycle related prognostic model for cervical cancer.Frontiers in genetics · 2023Article
- Monitoring cell endocytosis of liposomes by real-time electrical impedance spectroscopy.Analytical and bioanalytical chemistry · 2020Article
- Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations.Biomolecules · 2020Article
- Article
- Identification of putative drugs for gastric adenocarcinoma utilizing differentially expressed genes and connectivity map.Molecular medicine reports · 2019Article
- The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy.OncoTargets and therapy · 2019Article
- Insights into breast cancer phenotying through molecular omics approaches and therapy response.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature.Scientific reports · 2018Article
- In silico cancer research towards 3R.BMC cancer · 2018Review
- Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma.Wiley interdisciplinary reviews. Systems biology and medicine · 2018Review
- A Pyrazolo[3,4-Frontiers in pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With multiple omics strategies being applied to several cancer genomics projects, researchers have the opportunity to develop a rational planning of targeted cancer therapy. The investigation of such numerous and diverse pharmacogenomic datasets is a complex task. It requires biological knowledge and skills on a set of tools to accurately predict signaling network and clinical outcomes. Herein, we describe Web-based
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.